NEKTAR THERAPEUTICS
NKTRNasdaq
$68.26
↑ +1.8%Jul 17 close · end-of-day
Price
1Y↑ +182.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.7B
Enterprise Value
$1.1B
P/E
—
P/S
30.4
P/B
2.9
EV/EBITDA
—
PEG
—
FCF Yield
-12.1%
Dividend Yield
—
Revenue (TTM)
$55.6M
Net Income (TTM)
-$158.0M
Free Cash Flow (TTM)
-$203.9M
Gross Margin
—
Operating Margin
-242.0%
Net Margin
-284.0%
ROE
-27.4%
ROIC
-1397.1%
Debt / Equity
—
Net Cash
$568.6M
Return 1Y
+155.9%
Company profile
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinomas of the head and neck, and adjuvant melanoma. It is also developing NKTR-358, a cytokine Treg stimulant, in phase 2 clinical trial for the treatment of systemic lupus erythematosus
- CEO
- Howard W. Robin
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 220
- Headquarters
- California
- Website
- nektar.com
Management & directors
- Zalevsky JonathanChief R&D Officer
- Robin Howard WPresident & CEO
- Wilson Mark AndrewChief Legal Officer
Roles derived from SEC Form 4 filings.
Earnings
NKTR Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$10.9M↑ +3.8%
Diluted EPS-$1.82↓ -49.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $152.9M | $101.9M | $92.1M | $90.1M | $98.4M | $55.2M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$425.1M | -$446.1M | -$376.2M | -$263.7M | -$105.2M | -$140.1M |
| Net income | -$444.4M | -$524.0M | -$368.0M | -$276.0M | -$119.0M | -$164.0M |
| Diluted EPS | -$2.49 | -$2.86 | -$1.97 | -$1.45 | -$8.68 | -$9.73 |
| Operating cash flow | -$313.3M | -$412.7M | -$304.0M | -$192.6M | -$175.7M | -$208.5M |
| Free cash flow | -$320.5M | -$427.6M | -$309.7M | -$193.5M | -$177.2M | -$208.7M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -278.0% | -437.8% | -408.6% | -292.6% | -106.9% | -253.7% |
| Net margin | -290.6% | -514.2% | -399.8% | -306.3% | -120.9% | -296.9% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $23.5M | $24.1M | $29.2M | $10.5M | $11.2M | $11.8M | $21.8M | $10.9M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$49.8M | -$34.3M | $14.3M | -$44.5M | -$36.2M | -$31.7M | -$27.7M | -$39.1M |
| Net income | -$52.4M | -$37.1M | $7.2M | -$50.9M | -$41.6M | -$35.5M | -$36.0M | -$44.9M |
| Diluted EPS | -$3.76 | -$2.66 | -$2.07 | -$3.62 | -$2.95 | -$1.87 | -$1.29 | -$1.82 |
| Operating cash flow | -$37.7M | -$43.9M | -$46.2M | -$49.1M | -$45.7M | -$48.8M | -$65.0M | -$44.3M |
| Free cash flow | -$37.9M | -$44.6M | -$46.6M | -$49.1M | -$45.8M | -$48.9M | -$65.0M | -$44.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -211.9% | -142.4% | 49.2% | -425.8% | -324.2% | -268.6% | -126.9% | -359.6% |
| Net margin | -222.9% | -153.6% | 24.8% | -486.4% | -372.2% | -301.3% | -165.1% | -413.4% |
Company news
Jun 26, 2026
Jun 24, 2026
Jun 23, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | Zalevsky Jonathan· Chief R&D Officer | Sale | 5,681 | $70.00 | $397,670.00 | filing |
| 2026-06-17 | ROBIN HOWARD W· President & CEO | Sale | 5,500 | $60.81 | $334,455.00 | filing |
| 2026-06-17 | ROBIN HOWARD W· President & CEO | Sale | 4,500 | $61.65 | $277,425.00 | filing |
| 2026-06-16 | ROBIN HOWARD W· President & CEO | Sale | 5,303 | $59.97 | $318,020.91 | filing |
| 2026-06-16 | ROBIN HOWARD W· President & CEO | Sale | 4,697 | $60.71 | $285,154.87 | filing |
| 2026-06-15 | Zalevsky Jonathan· Chief R&D Officer | Sale | 5,538 | $60.71 | $336,211.98 | filing |
| 2026-05-19 | ROBIN HOWARD W· President & CEO | Sale | 444 | $65.51 | $29,086.44 | filing |
| 2026-05-19 | Zalevsky Jonathan· Chief R&D Officer | Sale | 199 | $65.51 | $13,036.49 | filing |
| 2026-02-18 | ROBIN HOWARD W· President & CEO | Sale | 423 | $73.00 | $30,879.00 | filing |
| 2026-02-18 | Zalevsky Jonathan· Chief R&D Officer | Sale | 180 | $73.00 | $13,140.00 | filing |
| 2026-01-20 | Zalevsky Jonathan· Chief R&D Officer | Sale | 3,867 | $35.67 | $137,935.89 | filing |
| 2025-12-22 | Zalevsky Jonathan· Chief R&D Officer | Award | 6,250 | $0.00 | $0.00 | filing |
| 2025-12-22 | ROBIN HOWARD W· President & CEO | Award | 21,667 | $0.00 | $0.00 | filing |
| 2025-11-25 | ROBIN HOWARD W· President & CEO | Sale | 2,207 | $54.28 | $119,795.96 | filing |
| 2025-11-25 | Zalevsky Jonathan· Chief R&D Officer | Sale | 1,157 | $54.28 | $62,801.96 | filing |
| 2025-11-25 | Wilson Mark Andrew· Chief Legal Officer | Sale | 630 | $54.28 | $34,196.40 | filing |
| 2025-11-21 | Zalevsky Jonathan· Chief R&D Officer | Award | 2,666 | $0.00 | $0.00 | filing |
| 2025-11-21 | Wilson Mark Andrew· Chief Legal Officer | Award | 1,903 | $0.00 | $0.00 | filing |
| 2025-11-21 | ROBIN HOWARD W· President & CEO | Award | 7,110 | $0.00 | $0.00 | filing |
| 2025-09-09 | ROBIN HOWARD W· President & CEO | Sale | 2,156 | $47.49 | $102,388.44 | filing |
| 2025-09-09 | ROBIN HOWARD W· President & CEO | Sale | 2,100 | $45.16 | $94,836.00 | filing |
| 2025-09-09 | ROBIN HOWARD W· President & CEO | Sale | 1,210 | $48.18 | $58,297.80 | filing |
| 2025-09-09 | ROBIN HOWARD W· President & CEO | Sale | 1,200 | $46.41 | $55,692.00 | filing |
| 2025-09-05 | ROBIN HOWARD W· President & CEO | Sale | 3,304 | $37.87 | $125,122.48 | filing |
| 2025-09-05 | ROBIN HOWARD W· President & CEO | Sale | 2,226 | $38.82 | $86,413.32 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.